The change applies to physician-administered and other Part B drugs starting Jan. 1, 2019.
The move followed analysis of five-year data in subjects.
The device is indicated for use in mild to moderate primary open-angle glaucoma in conjunction with cataract surgery.
Both companies plan to gain approval of new products within four years.
Company officials said the eye drop formulation is the first-ever topical biologic approved in ophthalmology.
In two Phase III trials, 51 percent of wet AMD patients maintained BCVA gains at the dosing level in the second year.
The topical treatment is the third prescription drug for the indication in the US.
CEO Mark Baum said his vision is for the company to be the most important pharmaceutical vendor to US ophthalmologists.
The government program will provide health insurance to 100 million poor families.
Market Scope forecasts robust growth in the country, with new regulations likely to expand access to health care.
Expanding access to care will offset declining use of photocoagulation for retinal disease.
The device is manipulated after implantation by a magnetic pen.
The companies will share equally in US profits and losses for EDIT-101.
The company said it expects to launch its twice-daily ocular corticosteroid in early 2019.
The company said the next step is to validate the software in clinical trials.
Other companies raised $21 million, bringing the total for the past month to $98.9 million.
The combined conference is Europe’s largest assembly of ophthalmologists and ophthalmic product vendors.
You are not currently logged in.
©2018 Market Scope
Lost your Password